Proposal for an Evidence Review Group on MDA, MSAT and FSAT
|
|
- Piers Morrison
- 5 years ago
- Views:
Transcription
1 Proposal for an Evidence Review Group on MDA, MSAT and FSAT Malaria Policy Advisory Committee Meeting WHO HQ Geneva, 11 September 2014 Dr A. Bosman and Dr P. Ringwald
2 Impact of MDA, MSAT and FSAT on malaria transmission VECTOR HUMAN LARVAL CONTROL larvae uninfected ADULT VECTOR CONTROL incubating infective infective incubating DIAGNOSIS & TREATMENT MSAT & FSAT MASS-DRUG ADMINISTRATION uninfected CONTROL OF MAN-VECTOR CONTACT WHO 98123
3 Resilience of malaria transmission The curves show probable growth of falciparum infection rates in epidemics assuming primary cases at time 0 (arrow) as 0.1 per cent of the population with falciparum infection, an incubation interval of 35 days, under the influence of different reproduction rates for malaria. (Adapted from the Bulletin of the World Health Organization, 1956, vol. 15:380)
4 Current WHO recommendations MDA mass treatment of all, or a large section, of the population whether symptoms are present or not Based on the review of results of 19 MDA projects during the period by von Seidlein and Greenwood 1 and a Technical Consultation held in , WHO concluded that there is little evidence that MDA is effective in reducing transmission although reduction in parasite prevalence and transient reduction in mortality and morbidity have been documented in some cases. 1 von Seidlein L, Greenwood BM (2003). Mass administration of antimalarial drugs. Trends in Parasitology, 19: Malaria epidemics: forecasting, prevention, early detection and control From policy to practice. Report of a WHO Informal Consultation, 8 10 December 2003.
5 Current WHO recommendations In 2010 a WHO consultation 3 reviewed the potential role of MDA in the context of artemisinin resistance in the Greater Mekong subregion based on evidence of impact of existing interventions, operational and modelling considerations. The consultation recommended immediate planning of a pilot MDA operation in western Cambodia or eastern Thailand and the collection of essential information on the safety and efficacy of the candidate drugs for MDA. 3 Consideration of mass drug administration for the containment of artemisinin resistant malaria in the Greater Mekong Subregion. Report of a WHO consensus meeting, 2010.
6 Current WHO recommendations The same consultation also reviewed the role of mass screening and treatment (MSAT/FSAT people in a broad/defined geographic area are screened, regardless of whether they have symptoms of malaria, providing treatment for those who test positive). MSAT generates important information on the epidemiology of malaria that can be useful for further containment efforts, but it is resource-intensive and logistically challenging - lack of fieldready, high-throughput, highly sensitive diagnostic tests. FSAT operationally more feasible than MSAT, this is not delivered in all villages simultaneously, and, therefore, it is unlikely to contribute significantly in elimination efforts. The contribution of MSAT and FSAT effective in reducing transmission needs to be confirmed.
7 Background A recent systematic review 4 of 32 studies assessed MDA in areas with different endemicity, with different medicines and dosages, different timings and number of rounds and concomitant implementation of vector control measures. The review concluded that MDA appears to quickly reduce malaria parasitaemia and several clinical outcomes, but more studies are required to assess its impact after 6 months, the barriers for community uptake and the potential contribution to the development of drug resistance. 4. Poirot et al., Mass drug administration for malaria. Cochrane Database of Systematic Reviews 2013, Issue 11. Art. No.: CD DOI: / CD pub2.
8 Background (continued) A subsequent review of the literature 5, including unpublished studies, identified 12 MDA studies demonstrating zero indigenous malaria cases in the target population maintained over six months after the end of drug administration. Over the last few years implementation research on MDA and FSAT have been conducted in Cambodia, and in other countries for which results are not yet in the public domain (e.g. FEMSE in Comoros, MDA in Zanzibar, MSAT in Zambia and MDA at Thai-Myanmar border). 5. UCSF Global Health Sciences. Review of mass drug administration and primaquine use: background paper prepared for the Bill & Melinda Gates Foundation, 2014 (unpublished document).
9 Impact of T3, MDA and LLINs in Anjouan Island (Comoros) Malaria reported cases: April 2010 Dec Formation personnel prise en charge (Juil10) Gratuité TDR et formation pour utilisation( mars.11) Distribution MILD (Déc10) Application Protocole Confirmer avant de traiter (Juin2011) Affectation Microscopistees (juil.11) Prise en charge gratuite des cas graves (Janv.12) Application strict du protocole de Prise En Charge du Paludisme (Juil.12) Traitement de mmsse pour l'élimination rapide du paludisme( Oct-Nov-Déc.12) 1 2 Distribution MILD permanet( Déc.13) Gratuite des ACT Avril2010 Suivi thérapeutique. Recherche active des cas. Contrôle ded qualité des lames; Déclaration obligatoire des cas ( Janv.13) Disponibilite des données (Avril 2010 ) T3 MDA LLIN 0 9
10 ERG preliminary list of questions (1-4) 1. Is there evidence of impact on malaria transmission at six month and one year following implementation of MDA, MSAT and FSAT? 2. What are the key determinants of "durable impact" on malaria of MDA, MSAT and FSAT? 3. What are the optimal conditions for application of MDA, MSAT and FSAT to reduce malaria transmission in terms of endemicity levels, combination of medicines and dosages, use of diagnostics, timings and number of MDA rounds, concomitant deployment of vector control interventions, IEC and pharmacovigilance? 4. What are the major limitations and challenges faced by multiple groups in the successful application of MDA, MSAT and FSAT to reduce malaria transmission?
11 ERG preliminary list of questions (5 8) 5. What is the specific role of MDA, MSAT and FSAT in the advanced phase of malaria elimination? 6. What is the specific role of MDA, MSAT and FSAT for the elimination of artemisinin resistant falciparum malaria? 7. What are the main knowledge gaps and what data need to be collected to recommend wider deployment of MDA, MSAT and FSAT as part of initiatives to reduce malaria transmission? 8. Which of methodological aspects and ethical requirements need to be considered by research groups and national ethical review boards for planning and assessment of studies on the durable impact of MDA, MSAT and FSAT on malaria transmission?
12 Discussion points for MPAC Refine ERG questions to be addressed Systematic reviews, and recent unpublished studies to be reviewed Methodological aspects and timing of ERG (tentative: 8-10 December 2014) Investigators/programme managers to include as presenters and reviewers Co-Chairpersons (from MPAC members) and Rapporteurs AOB
Evidence Review Group on MDA, MSAT and FSAT Malaria Policy Advisory Committee Geneva, Switzerland September 2015
Evidence Review Group on MDA, MSAT and FSAT Malaria Policy Advisory Committee Geneva, Switzerland 16-18 September 2015 Kevin Marsh Chairperson of the Evidence Review Group 1 Outline of the Presentation
More informationBMGF MALARIA STRATEGY TO 2020
BMGF MALARIA STRATEGY TO 2020 Supporting the Drive to Elimination in Mesoamerica & Hispaniola Diana Measham, DrPH, MSc Lead Eliminate Initiative September 25, 2014 The world has three potential future
More informationMalaria Policy Advisory Committee to the WHO: conclusions and recommendations of sixth biannual meeting (September 2014)
Malaria Journal This Provisional PDF corresponds to the article as it appeared upon acceptance. Fully formatted PDF and full text (HTML) versions will be made available soon. Malaria Policy Advisory Committee
More informationStrategy to move from accelerated burden reduction to malaria elimination in the GMS by 2030
Strategy to move from accelerated burden reduction to malaria elimination in the GMS by 2030 Dr Walter M Kazadi Coordinator Regional Hub Emergency Response to Artemisinin Resistance Regional Hub GMS MMV
More informationGlobal Report on Antimalarial Drug. and the Global Plan for Artemisinin Resistance Containment (GPARC)
Global Report on Antimalarial Drug Resistance and Drug Efficacy: 2-21 21 and the Global Plan for Artemisinin Resistance Containment (GPARC) MMV Stakeholders Meeting Dar es Salaam, Tanzania 2 June 211 Robert
More informationEighth intercountry meeting of national malaria programme managers from HANMAT and PIAM-Net countries
Summary report on the Eighth intercountry meeting of national malaria programme managers from HANMAT and PIAM-Net countries WHO-EM/MAL/384/E Islamabad, Pakistan 12 14 December 2016 Summary report on the
More informationWHO Global Malaria Programme. February 2009
WHO Global Malaria Programme February 2009 Table of Contents 1. The world malaria situation 2. The critical role of WHO's Global Malaria Programme 3. Our programme of work explained 4. Situation analysis
More informationProgress on the Containment of Artemisinin Tolerant Malaria Parasites in South-East Asia (ARCE) Initiative
Progress on the Containment of Artemisinin Tolerant Malaria Parasites in South-East Asia (ARCE) Initiative I. Background For many years, the border area between Cambodia and Thailand has been the source
More informationReport from the Global Malaria Programme. Dr Pedro L. Alonso, Director Malaria Policy Advisory Committee, Geneva, Switzerland, 16 March 2016
Report from the Global Malaria Programme Dr Pedro L. Alonso, Director Malaria Policy Advisory Committee, Geneva, Switzerland, 16 March 2016 Vision, goals, milestones and targets Vision: A world free of
More informationMedia centre Malaria. Key facts. Symptoms
Media centre Malaria Fact sheet Updated November 2017 Key facts Malaria is a life-threatening disease caused by parasites that are transmitted to people through the bites of infected female Anopheles mosquitoes.
More informationMalaria Situation and Plan for Elimination in China
Malaria Situation and Plan for Elimination in China Dr. Guan Yayi National Institute of Parasitic Diseases, China CDC Current Situation Contents Vivax malaria in China The Support from Global Fund Malaria
More informationMass drug Administration When Is It Useful
Mass drug Administration When Is It Useful Kwaku Poku Asante, MD MPH PhD Kintampo Health Research Centre, Ghana Malaria Control and Elimination 8-9 December 2016, Congress Center Basel, Switzerland MDA
More informationAntimalarial drug resistance
Antimalarial drug resistance Md Mushfiqur Rahman*, Leonard Ortega**, R M Rastogi* and Krongthong Thimasarn* Abstract Antimalarial drug resistance is of great concern in the WHO South-East Asia (SEA) Region.
More information54% WHO s emergency response to artemisinin resistance SHARP DECLINE IN MALARIA CASES AND DEATHS SEEN ACROSS THE GMS BULLETIN #5 SEPTEMBER 2016
BULLETIN #5 WHO s emergency response to artemisinin resistance SEPTEMBER 2016 SHARP DECLINE IN MALARIA CASES AND DEATHS SEEN ACROSS THE GMS 54% REDUCTION IN MALARIA CASES OVER 3 YEARS Increased access
More informationWhere are we with Malaria in Africa?
Where are we with Malaria in Africa? P.Olliaro WHO/TDR (Geneva, CH) U. Oxford (UK) Firenze 19Dec2012 1. Malaria receding focally Elimination (?) Consequences: Risks Syndromic approach to case-management
More informationA framework for malaria elimination
A framework for malaria elimination What s new? Dr Pedro Alonso, GMP Director Rationale for new malaria elimination framework The malaria landscape has changed dramatically since 2007 - Increased funding
More informationSupporting Accelerate to Zero: The BMGF Malaria Vector Control
Supporting Accelerate to Zero: The BMGF Malaria Vector Control Research Agenda NCAR-CDC Climate and Health Workshop Boulder CO 14 Jul 2015 Mike Reddy PhD MPH Dan Strickman MS PhD Malaria, (Prevent Transmission
More informationEvidence Review Group (ERG) on malaria elimination
Evidence Review Group (ERG) on malaria elimination Dr Richard Steketee, ERG chair MPAC meeting - Geneva, 14 September 2016 Rationale for an ERG on malaria elimination The malaria landscape has changed
More informationmass drug administration artemisinin resistant Consideration of for the Containment of malaria in the greater mekong subregion
Consideration of mass drug administration for the Containment of artemisinin resistant malaria in the greater mekong subregion RepoRt of a consensus meeting, 27 28 september 2010, geneva, switzerland WHO
More informationPHOTO: HYGEIA NIGERIA. Background Paper. Review of Mass Drug Administration and Primaquine Use
PHOTO: HYGEIA NIGERIA Background Paper Review of Mass Drug Administration and Primaquine Use Prepared for the Bill & Melinda Gates Foundation January 2014 Contents Acknowledgements... 2 Acronyms... 3 Introduction...
More informationThe drive towards malaria elimination
Malaria, Other Vectorborne and Parasitic Diseases Malaria Strategic issues The drive towards malaria elimination is on track in most endemic countries in the Region, based on the Regional Action Plan for
More informationA framework for malaria elimination. Dr Pedro Alonso, GMP Director
A framework for malaria elimination Dr Pedro Alonso, GMP Director Rationale for new elimination framework The malaria landscape has changed dramatically since 2007 Increased funding Large-scale implementation
More informationMinutes of the Drug Resistance and Containment Technical Expert Group
Minutes of the Drug Resistance and Containment Technical Expert Group 28 30 April 2014 Starling Hotel, Geneva, Switzerland Contents Acknowledgments... 3 Abbreviations... 4 Summary and recommendations...
More informationAgainst intervention No recommendation Strong Conditional Conditional Strong. For intervention. High Moderate Low Very low
Draft recommendation: Consider using MDA as an additional tool for the elimination of malaria in low prevalence island or nonisland settings where the risk of imported malaria is low Balance of desirable
More informationGlobal Report to MPAC: Sustaining the gains in malaria control and elimination. World Malaria Report Objectives
Global Report to MPAC: Sustaining the gains in malaria control and elimination Malaria Policy Advisory Committee Inaugural Meeting Geneva, Switzerland 31 January 2012 Robert D. Newman, MD, MPH Director,
More information1,3,7 New Strategy for Malaria surveillance in elimination phases in China. Prof. Gao Qi
1,3,7 New Strategy for Malaria surveillance in elimination phases in China Prof. Gao Qi Differences in control, elimination and post elimination phases Control Elimination Post Goal Reduce morbidity &
More informationVC TEG updates for MPAC Meeting, March 2013
VC TEG updates for MPAC Meeting, March 2013 Outline Call to establish a malaria vector control Technical Expert Group (TEG) Process to constitute the Technical Expert Group What are the immediate issues
More informationOpinion 19 February 2014
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 19 February 2014 EURARTESIM 320 mg/40 mg, film-coated tablet B/12 tablets (CIP: 34009 217 519 8 7) Applicant: SIGMA-TAU
More informationUpdating the Guidelines for the Treatment of Malaria
Updating the Guidelines for the Treatment of Malaria Meeting of the Malaria Policy Advisory Committee Geneva, 13-15 March, 2013 Prof. Nick White Co-chair, Chemotherapy Technical Expert Group With thanks
More informationConsensus modelling evidence to support the design of mass drug administration programmes
Malaria Policy Advisory Committee Meeting 16 18 September 2015, Geneva, Switzerland Background document for Session 1 Consensus modelling evidence to support the design of mass drug administration programmes
More informationMalaria Elimination: an Operational Manual
Malaria Elimination: an Operational Manual Update on behalf of GMP, WHO 3 May 2016 Malaria Elimination Field Manual Malaria Elimination Operational Manual The malaria landscape has changed dramatically
More informationRegional workshop on updating national strategic plans for the prevention of re-establishment of local malaria transmission in malaria-free countries
Summary report on the Regional workshop on updating national strategic plans for the prevention of re-establishment of local malaria transmission in malaria-free countries Casablanca, Morocco 18 20 October
More informationTechnical Guidance Note for Global Fund HIV Proposals
Technical Guidance Note for Global Fund HIV Proposals UNAIDS I World Health Organization I August 2011 Rationale for including pharmacovigilance in the proposal Pharmacovigilance is the science and activities
More informationMalaria Burden Estimation Evidence Review Group (MBE-ERG)
Malaria Burden Estimation Evidence Review Group (MBE-ERG) Peter Smith - Chair MBE-ERG (with thanks to Kathryn Andrews for drafting slides) MPAC meeting 13 th March, 2013 MBE-ERG: Terms of Reference To
More informationFrom a one-size-fits-all to a tailored approach for malaria control
From a one-size-fits-all to a tailored approach for malaria control MMV 12 th Stakeholders Meeting New Delhi, India 07 November 2012 Robert D. Newman, MD, MPH Director, Global Malaria Programme newmanr@who.int
More informationPreparing for the Next Global Threat A Call for Targeted, Decisive Action Now to Prevent The Next Pandemic
Preparing for the Next Global Threat A Call for Targeted, Decisive Action Now to Prevent The Next Pandemic Colin Ohrt, MD, MPH Founding Director, Consortium for Health Action Minnesota, USA; Hanoi, Vietnam;
More informationSingle dose primaquine as a P.falciparum gametocytocide
Single dose primaquine as a P.falciparum gametocytocide Cochrane Review Agreements and disagreements with other studies or reviews The findings of this review provide very little support for current WHO
More informationMALARIA ELIMINATION AND ERADICATION: HOPES, CHALLENGES, BARRIERS
MALARIA ELIMINATION AND ERADICATION: HOPES, CHALLENGES, BARRIERS 14 th Conference of the International Society of Travel Medicine 28 May 2015 Quebec, Canada Alan Magill MD Director, Malaria Bill & Melinda
More informationEnding Malaria in Nigeria: The WHO Agenda
Nigeria Institute of Medical Research 2016 World Malaria Day Lecture 27 April, 2016 Ending Malaria in Nigeria: The WHO Agenda Dr Tolu Arowolo Malaria Containment Programme, WHO, Nigeria arowolot@who.int
More informationMalaria Transmission Consortium. A multi-institution, 5-year malaria research project funded by the Bill & Melinda Gates Foundation
Malaria Transmission Consortium A multi-institution, 5-year malaria research project funded by the Bill & Melinda Gates Foundation MTC Participants University of Notre Dame Centers for Disease Control
More informationKey points and Q&A. A framework for malaria elimination (2017) Global Malaria Programme. Rationale for updated guidance.
Global Malaria Programme technical guidance Key points and Q&A A framework for malaria elimination (2017) This framework provides guidance on the tools, activities and strategies required to achieve malaria
More informationSummary World Malaria Report 2010
Summary The summarizes information received from 106 malaria-endemic countries and other partners and updates the analyses presented in the 2009 Report. It highlights continued progress made towards meeting
More informationProposed Evidence Review Group on assessment of malariogenic potential to inform elimination strategies and plans to prevent re-establishment
Proposed Evidence Review Group on assessment of malariogenic potential to inform elimination strategies and plans to prevent re-establishment Malaria Policy Advisory Committee Meeting Geneva, Switzerland
More informationReport of the First Meeting of the expert panel on health impact of Global fund investements
Geneva, 10 11 July 2014 Report of the First Meeting of the expert panel on health impact of Global fund investements 1/33 Contents Executive Summary... 3 Background... 4 Recommendations... 5 HIV... 5 TB...
More information14th Stakeholders Meeting
14th Stakeholders Meeting Steady progress towards malaria elimination: Interventions for today and tomorrow Denpasar, Bali 11 12 October 2017 Dr. Iriani Samad : INDONESIA S PROGRESS IN MALARIA ELIMINATION
More informationAssessing Surveillance Elements of the Zanzibar Malaria Elimination Program to. Support Malaria Elimination in Zanzibar. Shannon Kincaide Godbout
Assessing Surveillance Elements of the Zanzibar Malaria Elimination Program to Support Malaria Elimination in Zanzibar by Shannon Kincaide Godbout Duke Global Health Institute Duke University Date: Approved:
More informationAPPENDIX 1 DATA COLLECTION AND DISSEMINATION STEPS
APPENDIX 1 DATA COLLECTION AND DISSEMINATION STEPS 97 Country/ area APPENDIX 2a DRUG REGIMENS SEA REGION, 2001 (dosage for adults) : P. falciparum Lab confirmed Treatment failure Severe malaria Pregnancy
More informationMalaria Situation and Control in China
Malaria Situation and Control in China Dr Guan Yayi National Institute of Parasitic Diseases, China CDC March 16, 2010 Luang Prabang, Lao PDR Malaria in China (1952-2009) 0 50 100 150 200 250 300 1952
More informationRAM NEWSLETTER. Volume 2 Number 9
RAM NEWSLETTER. Volume 2 Number 9 My Rotary Friends and Friends of Rotary The main reason for getting this Newsletter out is to let everyone know about this year s Rotarians Against Malaria (RAM) Conference.
More informationClinical Analysis Report For Study Sample Study
Clinical Analysis Report For Study Sample Study Automated report generated by WWARN May 9, 2014 Falciparum class org.wwarn.csr.clinicalstudyreport Version 1.020140508-1558 1 Contents 1 Executive Summary
More informationThe PATH Innovation Pipeline for Malaria
path malaria learning series The PATH Innovation Pipeline for Malaria Transformative tools and approaches for defeating malaria Making progress against malaria requires collaboration across borders, sectors,
More informationSummary of the Eighth Meeting of the ITFDE (II) October 4, 2005
Summary of the Eighth Meeting of the ITFDE (II) October 4, 2005 The Eighth Meeting of the International Task Force for Disease Eradication (ITFDE) was convened at The Carter Center from 9:00am to 4:00pm
More informationMMV s Access & Product Management Strategy
MMV s Access & Product Management Strategy Siem Reap, Cambodia 24-26 February 2015 George Jagoe, EVP, Access & Product Mgmt Defeating Malaria Together OUR MISSION to reduce the burden of malaria in disease-endemic
More informationIs there Artemisinin Resistance in Western Cambodia?
Is there Artemisinin Resistance in Western Cambodia? Preliminary results, February 2008 Arjen Dondorp on behalf of the Task Force on Antimalarial Drug Resistance in Cambodia S769N PfATPase6 mutation Artemether
More informationENDEMIC MALARIA IN FOUR VILLAGES IN ATTAPEU PROVINCE, LAO PDR
ENDEMIC MALARIA IN FOUR VILLAGES IN ATTAPEU PROVINCE, LAO PDR R Phetsouvanh 1, I Vythilingam 2, B Sivadong 1, S Lokman Hakim 2, ST Chan 2 and S Phompida 1 1 Center for Malaria, Parasitology and Entomology,
More informationMalaria. Dr. Salim Abdulla, Director Ifakara Health Institute, Dar-es-salaam, Tanzania
Malaria Dr. Salim Abdulla, Director Ifakara Health Institute, Dar-es-salaam, Tanzania Despite 42% reduction since 2000, a child dies every minute in Africa from malaria 207 million malaria cases in 2012,
More informationUpdating the Malaria Vaccine Technology Roadmap
Updating the Malaria Vaccine Technology Roadmap Vasee Moorthy MRCP PhD MPAC 14 March 2013 Purpose of this MPAC session MPAC to be updated on the strategic R&D framework for malaria vaccines, including
More informationMESA research grants 2014
MESA research grants 2014 MESA operational research grant Principal investigator Mopping up and getting to zero: mapping residual malaria transmission for targeted response in urban Lusaka, Zambia. Daniel
More informationEthiopia Malaria Financial Landscape
Ethiopia Malaria Financial Landscape PATH MACEPA DECEMBER 2015 MALARIA FUNDING IN ETHIOPIA AT A GLANCE The total estimated cost to implement Ethiopia s National Malaria Strategic Plan (NMSP) for 2015 2017
More informationINTERMITTENT PREVENTIVE TREATMENT OF MALARIA IN PREGNANCY WITH SULPHADOXINE/PYRIMETHAMINE
INTERMITTENT PREVENTIVE TREATMENT OF MALARIA IN PREGNANCY WITH SULPHADOXINE/PYRIMETHAMINE WHO EVIDENCE REVIEW GROUP WHO, Geneva, July 9 th 11 th 2012 MPAC MEETING September 11 th - 13 th 2012 CURRENT WHO
More informationMalaria Elimination: Future Reality?
Malaria Elimination: Future Reality? Global Health Mini University March 4, 2016 Outline Highlight tremendous progress recorded in malaria control Discuss key challenges to further progress Highlight new
More informationAide Mémoire. 1. Purpose
Aide Mémoire Namibia Malaria Program Performance Review 1. Purpose The National Vector-borne Diseases Control Programme (NDVCP) within the Directorate of Special Programmes (DSP) in the Ministry of Health
More informationMONITORING THE THERAPEUTIC EFFICACY OF ANTIMALARIALS AGAINST UNCOMPLICATED FALCIPARUM MALARIA IN THAILAND
SOUTHEAST ASIAN J TROP MED PUBLIC HEALTH MONITORING THE THERAPEUTIC EFFICACY OF ANTIMALARIALS AGAINST UNCOMPLICATED FALCIPARUM MALARIA IN THAILAND C Rojanawatsirivej 1, S Vijaykadga 1, I Amklad 1, P Wilairatna
More informationMalaria DR. AFNAN YOUNIS
Malaria DR. AFNAN YOUNIS Objectives: Epidemiology of malaria Clinical picture Mode of transmission Risk factors Prevention and control Malaria is a life-threatening disease caused by Plasmodium parasites
More informationMekong Malaria Elimination
Mekong Malaria Elimination Hiromasa Okayasu Coordinator, MME March 2018 Global Malaria Programme Malaria is caused by Parasite (Plasmodium) 2 Distribution of Vectors Human malaria is transmitted only by
More informationIMPLEMENTING RISK MANAGEMENT PLANS IN AFRICA: THE ASAQ Winthrop RISK MANAGEMENT PLAN. François Bompart Access to Medicines - Sanofi
IMPLEMENTING RISK MANAGEMENT PLANS IN AFRICA: THE ASAQ Winthrop RISK MANAGEMENT PLAN François Bompart Access to Medicines - Sanofi Artesunate Amodiaquine Winthrop (ASAQ Winthrop ) Infant (
More informationJournal Assignment #2. Malaria Epidemics throughout the World
Journal Assignment #2 Malaria Epidemics throughout the World In this assignment, you will study malaria and how it has impacted several world regions and how its global impact has had devastating effects
More informationPh.D. Thesis: Protective immune response in P.falciparum malaria 2011 CHAPTER I: Introduction. S.D. Lourembam 16
CHAPTER I: Introduction S.D. Lourembam 16 1. INTRODUCTION Malaria remains a major global health problem with 300 to 500 million clinical infections and more than a million deaths reported each year. In
More informationJTEG s RTS,S/AS01Candidate Policy Recommendations
JTEG s RTS,S/AS01Candidate Policy Recommendations Peter Smith On behalf of the Joint Technical Expert Group JTEG Candidate Policy Recommendations Introductory remark: There is a need to evaluate pilot
More informationThe President s Malaria Initiative (PMI) Indoor Residual Spraying (IRS) in Motion: Malaria Stories from the Field
The President s Malaria Initiative (PMI) Indoor Residual Spraying (IRS) in Motion: Malaria Stories from the Field Presenters: Allison Belemvire, Christen Fornadel & Kristen George Presentation Outline
More informationSatimai et al. Malaria Journal 2012, 11:300
Satimai et al. Malaria Journal 2012, 11:300 RESEARCH Open Access Artemisinin resistance containment project in Thailand. II: responses to mefloquine-artesunate combination therapy among falciparum malaria
More informationRoadmaps as a Vehicle for Addressing Large- Scale Public Health Challenges: Lessons from the Malaria Vaccine Technology Roadmap
Background to development of vaccine roadmaps, to include priority areas for research, product development, capacities, and policy and commercialization Roadmaps as a Vehicle for Addressing Large- Scale
More informationDeveloping Logic Models
Developing Logic Models Developing Logic Models 2 An introduction to using Logic Models in CIDG reviews. What are Logic Models? Logic models are diagrams which map out important concepts within a systematic
More informationPoliovirus : éradication pour les prochaines JNI?
Poliovirus : éradication pour les prochaines JNI? Bruno LINA CNR des entérovirus Laboratoire de virologie EST, GHE, HCL FRE 3011 CNRS UCBL, Lyon Polio Eradication Initiative 1 Polio Eradication Progress
More informationFighting Harder and Smarter Against Malaria. Dr.Bernard Nahlen Deputy US Global Malaria Coordinator University of Georgia, February 23, 2010
Fighting Harder and Smarter Against Malaria Dr.Bernard Nahlen Deputy US Global Malaria Coordinator University of Georgia, February 23, 2010 Outline Burden of malaria Global support for rolling back malaria
More informationPreliminary investigation of the impact of mass drug administration on malaria transmission in Zanzibar.
THE SAHLGRENSKA ACADEMY Preliminary investigation of the impact of mass drug administration on malaria transmission in Zanzibar. Degree Project in Medicine Marcus Fredriksson Programme in Medicine Gothenburg,
More informationDisease Narrative for Malaria and Areas for Intervention
Disease Narrative for Malaria and Areas for Intervention ADAPTED FROM CONTENT DEVELOPED FOR PRESENTATION TO UNITAID EXECUTIVE BOARD FOR ITS 23 MEETING (11/2015) Executive Summary In the past 15 years,
More informationDriving access to medicine
Driving access to medicine An example from the Novartis Malaria Initiative Hans Rietveld Director, Market Access & Capacity Building Novartis Malaria Initiative Social Forum - Geneva February 20, 2015
More information26/06/ NIMR 2018 Conference - Malaria - a reality
Malaria Elimination: Reality or Myth? Wellington A. Oyibo ANDI CENTRE OF EXCELLENCE FOR MALARIA DIAGNOSIS WHO/FIND Malaria Specimen Collection Site The International Center for Malaria Microscopy and Malaria
More informationMinutes of the Technical Expert Group (TEG) on Drug Efficacy and Response
Malaria Policy Advisory Committee Meeting 16 17 March 2016, Geneva, Switzerland Background document for Session 3 Minutes of the Technical Expert Group (TEG) on Drug Efficacy and Response Crowne Plaza
More informationSummary of the Ninth Meeting of the ITFDE (II) May 12, 2006 (revised)
Summary of the Ninth Meeting of the ITFDE (II) May 12, 2006 (revised) The Ninth Meeting of the International Task Force for Disease Eradication (ITFDE) was convened at The Carter Center from 9:00am to
More informationNew Partnerships The Development of ASMQ - FDC
New Partnerships The Development of ASMQ - FDC Jean-René Kiechel Senior Product Manager DNDi January 2011 1 ACTs: World Health Organization Treatment Guidelines (2006) In order to fight resistance: 1.
More informationMalaria Control. Umberto D Alessandro
Malaria Control Umberto D Alessandro Zanzibar - hospitalizations et malaria deaths 1999-2008 2 The Gambia - slide positivity rates 2003-2009 Under-5 mortality rate (per 1,000 live births) 300 250 200 150
More informationMalaria elimination in Jiangsu China
Malaria elimination in Jiangsu China Prof. Gao Qi Jiangsu Institute of Parasitic Diseases, P.R. China APMEN VI Annual Business and Technical meeting Manila, The Philippines March 11-13, 2014 Geographical
More informationNOTABLE EVENTS IN NATIONAL POLICY AND FINANCING FOR MALARIA
Malaria Policy Landscape PATH MACEPA JULY 2016 OVERVIEW API 2014 PATH MACEPA has been working in partnership with s Federal Ministry of Health (FMOH) since 2007 and the Amhara Regional Health Bureau (ARHB)
More informationOverview of Malaria Status in Zanzibar & National Strategic Plan - 25 April 2014 Zanzibar Malaria Elimination Programme Abdullah Ali Manager.
Overview of Malaria Status in Zanzibar & National Strategic Plan - 25 April 2014 Zanzibar Malaria Elimination Programme Abdullah Ali Manager. Outline Malaria epidemiology Surveillance Systems Malaria Early
More informationGlobal Fund: Malaria in Pregnancy Perspectives
Global Fund: Malaria in Pregnancy Perspectives Dr. Roopal Patel, Malaria Advisor Malaria in Pregnancy Working Group Annual Meeting Geneva, Switzerland September 18, 2017 Strengthening systems for health
More informationPopulation-Wide Drug-Based Strategies for Malaria Elimination
path malaria learning series Population-Wide Drug-Based Strategies for Malaria Elimination Assessing impact, operational requirements, and cost across three African settings the path malaria learning series
More informationManuscripts for the WHO Evidence Review Group for malaria in pregnancy (MiP-ERG), July 2015
Malaria Policy Advisory Committee Meeting 5 7 March 2015, Geneva, Switzerland Background document for Session 4 Manuscripts for the WHO Evidence Review Group for malaria in pregnancy (MiP-ERG), July 2015
More informationREVIEW THE CHALLENGES OF MALARIA ELIMINATION IN YUNNAN PROVINCE, PEOPLE S REPUBLIC OF CHINA
Malaria elimination in Yunnan, PR China REVIEW THE CHALLENGES OF MALARIA ELIMINATION IN YUNNAN PROVINCE, PEOPLE S REPUBLIC OF CHINA Jianwei Xu and Hui Liu Yunnan Institute of Parasitic Diseases, Puer,
More informationVector control and policy: systematic reviews
Vector control and policy: systematic reviews Funding source I am funded by UKAid to increase decisions based on reliable evidence in health in LMIC I am responsible for the WHO Collaborating Centre for
More informationConditions for use of long-lasting insecticidal nets treated with a pyrethroid and piperonyl butoxide
Global Malaria Programme Conditions for use of long-lasting insecticidal nets treated with a pyrethroid and piperonyl butoxide 21 23 September 2015 Geneva, Switzerland WHO Evidence Review Group Meeting
More informationMalaria Risk Areas in Thailand Border
Malaria Risk Areas in Thailand Border Natthawut Kaewpitoon PhD*, **, Ryan A Loyd MD***, Soraya J Kaewpitoon MD**, ***, Ratana Rujirakul MEd** * Faculty of Public Health, Vongchavalitkul University, Nakhon
More informationTECHNICAL REPORT SECOND SLIDE PANEL EXTERNAL QUALITY ASSURANCE PROGRAM FOR MALARIA MICROSCOPY DIAGNOSIS
TECHNICAL REPORT SECOND SLIDE PANEL 2012-2013 EXTERNAL QUALITY ASSURANCE PROGRAM FOR MALARIA MICROSCOPY DIAGNOSIS REGIONAL MALARIA PROGRAM NEGLECTED, TROPICAL AND VECTOR-BORNE DISEASES COMMUNICABLE DISEASES
More informationMalaria Vaccine Implementation Programme (MVIP) update and framework for policy decision. Mary J Hamel, WHO MPAC, 11 April 2018
Malaria Vaccine Implementation Programme (MVIP) update and framework for policy decision Mary J Hamel, WHO MPAC, 11 April 2018 MVIP update Background to MVIP MVIP Updates Regulatory Vaccine introduction
More informationCombination Anti-malarial Therapy and WHO Recommendations
Prakaykaew Charunwatthana 2, and Sasithon Pukrittayakamee 1,2 1 Associate Fellow of the Royal Institute, Academy of Science 2 Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol
More informationDengue Haemorrhagic Fever in Thailand
By Wiwat Rojanapithayakorn Office of Dengue Control, Department of Communicable Diseases Control, Ministry of Public Health, Thailand Abstract Dengue haemorrhagic fever was first reported in Thailand in
More informationOverview of Malaria Epidemiology in Ethiopia
Overview of Malaria Epidemiology in Ethiopia Wakgari Deressa, PhD School of Public Health Addis Ababa University Symposium on Neuro-infectious Disease United Nations Conference Center, AA February 28,
More informationMalaria Surveillance Bulletin
Malaria Surveillance Bulletin MALARIA CONTROL UNIT NAIROBI, KENYA ISSUE 9 JUNE 214 The MALARIA SURVEILLANCE BULLETIN is produced by the Malaria Control Unit and is a quarterly production. EDITORIAL TEAM
More informationASIA PACIFIC MALARIA GUIDE A QUICK REFERENCE FOR JOURNALISTS AND OTHERS INTERESTED IN MALARIA AND ITS ELIMINATION IN THE ASIA PACIFIC
ASIA PACIFIC MALARIA GUIDE A QUICK REFERENCE FOR JOURNALISTS AND OTHERS INTERESTED IN MALARIA AND ITS ELIMINATION IN THE ASIA PACIFIC ACRONYMS AND ABBREVIATIONS ACT APLMA APMEN bn CDC DDT DOT FDA GHG IPT
More information